Multiple Sclerosis and Related Disorders

Article	Citations
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?	127
Multiple sclerosis following SARS-CoV-2 infection	124
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran	118
Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain	110
Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients	109
Effects of MS disease-modifying therapies on responses to vaccinations: A review.	104
How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms	102
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment	85
Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States	79
A case of possible atypical demyelinating event of the central nervous system following COVID-19	75
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.	73
Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis	69
Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: A case report	68
Anxiety and depression in Multiple Sclerosis (MS): Antecedents, consequences, and differential impact on well-being and quality of life	66
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod	63
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic	60
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review	60
Infections in patients diagnosed with multiple sclerosis: A multi-database study	57
Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak	56
Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study	56
Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab	53
Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study	52
Long COVID or post COVID-19 syndrome	52
The effect of aquatic physical therapy on patients with multiple sclerosis: A systematic review and meta-analysis	51
COVID-19 in ocrelizumab-treated people with multiple sclerosis	51

Genetic Acute Necrotizing Encephalopathy Associated with RANBP2: Clinical and Therapeutic Implications in Pediatrics	49
COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies	49
Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review	48
MOG-associated encephalitis following SARS-COV-2 infection	46
COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series	46
Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice	45
Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis	45
A literature review of cost-of-illness studies on the economic burden of multiple sclerosis.	44
COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021	44
Effect of video-based exergaming on arm and cognitive function in persons with multiple sclerosis: A randomized controlled trial	41
Prodromal headache in MOG-antibody positive optic neuritis	41
Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?	40
The Symbol Digit Modalities Test (SDMT) is sensitive but non-specific in MS: Lexical access speed, memory, and information processing speed independently contribute to SDMT performance	39
Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: Two paradigmatic cases and a review of the literature	39
Epidemiology of pediatric multiple sclerosis: A systematic literature review and meta-analysis	38
Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases	38
Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients	38
OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis	37
A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis	37
Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19	37
COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?	37
Willingness to be vaccinated against COVID-19: An exploratory online survey in a Portuguese cohort of multiple sclerosis patients	36
Effectiveness of Virtual Reality Rehabilitation in Persons with Multiple Sclerosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials	36
Clinical analysis of anti-NMDAR encephalitis combined with MOG antibody in children	36
Autoimmune encephalitis associated with COVID-19: A systematic review	36
Upper limb rehabilitation interventions using virtual reality for people with multiple sclerosis: A systematic review	36
Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis	36
Rethinking high-risk groups in COVID-19	35
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice	35
Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England	35
COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach	35
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies	35
Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD)	35
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis	34
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19	34
The Clinical Features and Prognosis of Anti-NMDAR Encephalitis Depends on Blood Brain Barrier Integrity	33
COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America	33
COVID-19 vaccine associated demyelination & its association with MOG antibody	32
Socioeconomic status and race are correlated with affective symptoms in multiple sclerosis	32
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report	32
Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis	32
Feasibility and treatment effect of cognitive behavioral therapy for insomnia in individuals with multiple sclerosis: A pilot randomized controlled trial	32
Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis	32
Patients' perspective and usability of innovation technology in a new rehabilitation pathway: An exploratory study in patients with multiple sclerosis	32
Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica	32
T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers	31
Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy	31
Adherence and drop-out in randomized controlled trials of exercise interventions in people with multiple sclerosis: A systematic review and meta-analyses	31
Infections in patients with multiple sclerosis: A national cohort study in Sweden	31
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects	31

Phase I randomized trial of liothyronine for remyelination in multiple sclerosis: A dose-ranging study with assessment of reliability of visual outcomes	30
Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia	30
Fear of falling and falls in people with multiple sclerosis: A literature review	30
Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab	30
Multiple sclerosis and aging: comorbidity and treatment challenges	30
Chronic fatigue and depression due to multiple sclerosis: Immune-inflammatory pathways, tryptophan catabolites and the gut-brain axis as possible shared pathways	30
Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis	29
Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis	29
Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: A case-series	29
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis	29
Social cognition in multiple sclerosis and its subtypes: A meta-analysis	29
Evolution and resolution of brain involvement associated with SARS- CoV2 infection: A close Clinical – Paraclinical follow up study of a case	29
Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab	29
Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases	29
Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review	28
Combined exercise training improves cognitive functions in multiple sclerosis patients with cognitive impairment: A single-blinded randomized controlled trial	28
Efficacy of robot-assisted gait training in multiple sclerosis: A systematic review and meta-analysis	28
Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?	27
Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic	27
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis	27
New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19	27
Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use	27
COVID-19 and emerging spinal cord complications: A systematic review	27
Anti-MOG associated disorder–Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD–A single-center experience	27
Physical activity behavior in people with multiple sclerosis during the COVID-19 pandemic in Israel: Results of an online survey	26
Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with Multiple Sclerosis	26
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab	26
Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration	26
Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness	26
Fear and anxiety in patients with multiple sclerosis during COVID-19 pandemic; report of an Iranian population	26
COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab	25
Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy	25
A new look at an old test: Normative data of the symbol digit modalities test –Oral version	25
Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data	25
Long-term dynamics of multiple sclerosis iron rim lesions	25
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial	25
Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience	25
Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies	25
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab	25
Depression in multiple sclerosis: Is one approach for its management enough?	24
Distress and risk perception in people living with multiple sclerosis during the early phase of the COVID-19 pandemic	24
Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia	24
Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients	24
Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab	24
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients	24
Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials	24
Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis	23
Refining cell-based assay to detect MOG-IgG in patients with central nervous system inflammatory diseases	23
The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades	23
Characteristics of COVID-19 disease in multiple sclerosis patients	23
Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis	23
Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder.	23
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience	23
An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014–2017	22
Epidemiology and comorbidities of adult multiple sclerosis and neuromyelitis optica in Taiwan, 2001–2015	22
An overview of lipidomic analysis in different human matrices of multiple sclerosis	22
Multiple sclerosis incidence: A systematic review of change over time by geographical region	22
Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD	22
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years	22
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS	22
Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis	21
How the COVID-19 Pandemic has changed multiple sclerosis clinical practice: Results of a nationwide provider survey	21
Serum malondialdehyde as a lipid peroxidation marker in multiple sclerosis patients and its relation to disease characteristics	21
A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis	21
Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis	21
Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: A systematic review	21
Development and validation of the self-reported disability status scale (SRDSS) to estimate EDSS-categories	21
Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters	21
Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study	21
Normal antibody response after COVID-19 during treatment with cladribine	21
Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge	21
Tired of not knowing what that fatigue score means? Normative data of the Modified Fatigue Impact Scale (MFIS)	21
Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study	21
Vaccine hesitancy among people with multiple sclerosis	21
Effects on gait and balance of home-based active video game interventions in persons with multiple sclerosis: A systematic review	20
African Americans experience disproportionate neurodegenerative changes in the medulla and upper cervical spinal cord in early multiple sclerosis	20
Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod	20
Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab	20
Cerebrospinal fluid cytokine, chemokine, and SARS-CoV-2 antibody profiles in children with neuropsychiatric symptoms associated with COVID-19	20
Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study	20

The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?	20
Incidence and prevalence of multiple sclerosis in persian gulf area: A systematic review and meta-analysis	20
Longitudinally extensive transverse myelitis following acute COVID-19 infection	20
Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran	20
High or increasing serum NfL is predictive of impending multiple sclerosis relapses	20
Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis	20
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis	20
Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder	20
Autoimmune glial fibrillary acidic protein astrocytopathy mimics infectious meningitis: Two case reports	20
NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS	20
Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients	20
Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy	20
Changes in Th17 cells frequency and function after ozone therapy used to treat multiple sclerosis patients	20
The role of cognitive reserve in multiple sclerosis: A cross-sectional study in 526 patients	19
Status of the neuromyelitis optica spectrum disorder in Latin America	19
Seizure occurrence in myelin oligodendrocyte glycoprotein antibody-associated disease: A systematic review and meta-analysis	19
Efficacy and safety of rituximab in multiple sclerosis: Experience from a developing country	19
¿ Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis	19
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program	19
Validation of inter-eye difference thresholds in optical coherence tomography for identification of optic neuritis in multiple sclerosis	19
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies	19
Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran	19
Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil	19
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study)	19
One Aspect of Coronavirus disease (COVID-19) Outbreak in Iran: High Anxiety among MS Patients	19
Neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio are associated with a 2-year relapse in patients with multiple sclerosis	19
Early predictors of conversion to secondary progressive multiple sclerosis	19
Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients	19
Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic	19
Multiple sclerosis epidemiology in Asia and Oceania; A systematic review and meta-analysis	19
The effect of aerobic exercise on Neurofilament light chain and glial Fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis	19
Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate	18
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis	18
Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study	18
Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets	18
Artificial intelligence in the diagnosis of multiple sclerosis: A systematic review	18
Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod	18
Differential patterns of parafoveal and peripapillary vessel density in multiple sclerosis and neuromyelitis optica spectrum disorder	18
Home-Based Exercise Training in Multiple Sclerosis: A Systematic Review with Implications for Future Research	18
Smartphone applications to assess gait and postural control in people with multiple sclerosis: A systematic review	18
Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab	18
Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?	18
The rs4759314 SNP within Hotair lncRNA is associated with risk of multiple sclerosis	18
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder	18
COVID-19 in MS and NMOSD: A multicentric online national survey in Chile	18
Effects of a 10-week multimodal dance and art intervention program leading to a public performance in persons with multiple sclerosis - A controlled pilot-trial	18
CNS demyelination during tofacitinib therapy: First report	18
The impact of balance specific physiotherapy, intensity of therapy and disability on static and dynamic balance in people with multiple sclerosis: A multi-center prospective study	18
Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood–brain barrier breakdown and peripheral plasmablasts	18
How personality traits affect functional outcomes in patients with multiple sclerosis: A scoping review on a poorly understood topic	18
Use of natalizumab in persons with multiple sclerosis: 2022 update	18
To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection	17
Under-treated depression negatively impacts lifestyle behaviors, participation and health-related quality of life among older people with multiple sclerosis	17
Challenges in multiple sclerosis care: Results from an international mixed-methods study	17
Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland	17
Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses	17
Sex-specific differences in rim appearance of multiple sclerosis lesions on quantitative susceptibility mapping	17
COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID	17
Idebenone does not inhibit disability progression in primary progressive MS	17
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies	17
“FLAMES: A novel burning entity in MOG IgG associated disease”	17
Aseptic meningitis as an atypical manifestation of neuromyelitis optica spectrum disorder flare	17
Fatigue and fluctuations in physical and psychological wellbeing in people with multiple sclerosis: A longitudinal study	17
Exercise improves neurotrophins in multiple sclerosis independent of disability status	17
The effect of the Australian bushfires and the COVID-19 pandemic on health behaviours in people with multiple sclerosis	17
Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases	17
A pilot randomized controlled trial of robotic exoskeleton-assisted exercise rehabilitation in multiple sclerosis	17
Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study	17
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis	17
“No evidence of disease activity”: Is it an aspirational therapeutic goal in multiple sclerosis?	17
Blood levels of brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis (MS): A systematic review and meta-analysis	17
Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study	17
Details and outcomes of a large cohort of MOG-IgG associated optic neuritis	17
Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar	17
Aquatic exercising may improve sexual function in females with multiple sclerosis – an exploratory study	16
Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis	16
The cellular immune response against Epstein-Barr virus decreases during ocrelizumab treatment	16
NfL levels predominantly increase at disease onset in MOG-Abs-associated disorders	16
Incidence of cancer in multiple sclerosis before and after the treatment era– a registry- based cohort study	16
Circulating levels of tight junction proteins in multiple sclerosis: Association with inflammation and disease activity before and after disease modifying therapy	16
Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.	16
Backward walking sensitively detects fallers in persons with multiple sclerosis	16
MSCOVID19: Using social media to achieve rapid dissemination of health information	16
The importance of gut-brain axis and use of probiotics as a treatment strategy for multiple sclerosis	16
Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?	16
High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics	16
The prevalence of cognitive impairment in patients with neuromyelitis optica spectrum disorders (NMOSD): A systematic review and meta-analysis	16
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab	16
Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?	16
Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies	16
SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine	16
Serotoninergic system targeting in multiple sclerosis: the prospective for pathogenetic therapy.	16
Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC)	16
MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis	16
Working ability in individuals with different disease courses of multiple sclerosis: Factors beyond physical impairment	16